Emergence of Delafloxacin-Resistant Staphylococcus aureus in Brooklyn, NY.
Delafloxacin is an option for infections due to methicillin-resistant Staphylococcus aureus. In 2017, 22% of isolates from seven hospitals in Brooklyn, NY were nonsusceptible to delafloxacin. Isolates belonging to ST105, a strain associated with healthcare-related infections, predominated. Resistance was also found in ST8, a strain (USA300) associated with community-associated infections.